Report Description Table of Contents Chest Drainage System Market Size, Share, Trends, Segmentation & Forecast, 2026–2032 – (Updated On: 29-Aug-2026) The Global Chest Drainage System Market was valued at USD 1.08 billion in 2025 and is projected to reach USD 1.67 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032, according to Strategic Market Research. Chest drainage systems comprise thoracic drainage tubes or catheters, collection chambers and dedicated suction or digital drainage platforms used to evacuate air, blood or pleural fluid and maintain controlled negative pressure. They are used mainly after thoracic and open cardiac surgery and in pneumothorax, pleural effusion, pleural infection and thoracic trauma. SMR treats cardiothoracic procedure volumes as indicators of the addressable clinical workload, not as one-to-one device sales, because drainage use varies by procedure, surgical approach, number of tubes and local removal protocols. The clinical base is substantial. STS reports about 8.5 million adult cardiac surgery records and participation from more than 95% of U.S. groups performing cardiac surgery. Japan recorded 94,961 general thoracic procedures in 2024, including 49,541 for primary lung cancer and 14,719 for pneumothorax. England recorded 72,275 spontaneous-pneumothorax admissions among 59,130 patients from January 2017 to March 2023. These datasets show the recurring procedural workload underlying hospital chest-drain utilization. [1] [2] [3] The newest chest drainage technology is shifting from traditional water-seal and analog suction bottles to smart digital systems. Devices such as Medela Thopaz+ and Thoraguard provide objective air-leak and fluid measurements, replacing visual bubble assessment. Battery-powered suction maintains consistent negative pressure without continuous wall suction, while compact designs support earlier patient mobility. By providing real-time drainage data, these systems improve chest-tube management, support earlier tube removal, and may help shorten postoperative hospital stays after thoracic surgery. What Are the Key Chest Drainage System Market Takeaways? By Product Type Thoracic Drainage Tubes: 46.0% share, USD 0.497 billion in 2025 and 6.1% CAGR; the largest category because the catheter is the core interface for postoperative, pleural and trauma drainage. Collection Chambers: 34.0% share, USD 0.367 billion and 6.5% CAGR; recurring single-patient use sustains a large consumables revenue pool. Suction Devices: 20.0% share, USD 0.216 billion and 7.0% CAGR; the fastest product segment as digital and portable regulated-suction platforms gain share in cardiothoracic care. By Application Pneumothorax Treatment: 22.0% share, USD 0.238 billion and 6.7% CAGR; emergency and respiratory pathways support recurring utilization. Pleural Effusion Management: 27.0% share, USD 0.292 billion and 6.4% CAGR; malignant effusion and pleural infection create substantial drainage activity. Post-Surgical Care: 38.0% share, USD 0.410 billion and 6.0% CAGR; the largest application because chest drainage is embedded in thoracic and open cardiac postoperative pathways. Trauma Care: 13.0% share, USD 0.140 billion and 7.2% CAGR; rapid treatment of traumatic pneumothorax and hemothorax favors dependable, high-capacity systems. By End User Hospitals: 61.0% share, USD 0.659 billion and 5.9% CAGR; operating rooms, ICUs, emergency departments and cardiothoracic wards form the primary purchasing base. Surgical Centers: 18.0% share, USD 0.194 billion and 6.8% CAGR; this category primarily reflects specialty surgical hospitals and hospital-affiliated procedure centers rather than routine freestanding ASC cardiac surgery. Clinics: 12.0% share, USD 0.130 billion and 6.7% CAGR; use is concentrated in selected pleural, respiratory and follow-up pathways. Homecare Providers: 9.0% share, USD 0.097 billion and 8.4% CAGR; ambulatory systems support selected patients outside conventional inpatient wards. By Geography North America: 39.0% share, USD 0.421 billion and 5.8% CAGR. Europe: 27.0% share, USD 0.292 billion and 5.9% CAGR. Asia-Pacific: 23.0% share, USD 0.248 billion and 8.0% CAGR. Latin America: 6.0% share, USD 0.065 billion and 6.6% CAGR. Middle East & Africa: 5.0% share, USD 0.054 billion and 6.7% CAGR. What Exactly Is Included in the Chest Drainage System Market? SMR defines the market as revenue from dedicated thoracic drainage tubes/catheters, single-patient collection chambers and dedicated portable or digital chest-drain suction platforms used for pleural or mediastinal drainage. Revenue is assigned to the primary invoiced product category to avoid double counting bundled systems. General hospital wall-vacuum infrastructure, non-thoracic wound drains, pleurodesis drugs and thoracentesis-only needles are excluded. Ambulatory thoracic drains are included when their principal purpose is continued pleural drainage; broader home fluid-management products are excluded. The market contains two business models: conventional systems generate revenue mainly through disposable tubes, chambers and kits, while digital systems add reusable controllers with recurring canisters, tubing and accessories. High-volume disposables therefore coexist with premium digital conversion in selected cardiothoracic centers. Which Procedures Create the Largest Addressable Chest-Drainage Base? Post-surgical care accounted for 38.0% of the market, or USD 0.410 billion in 2025, with a 6.0% CAGR. Thoracic resection and open cardiac surgery are the most predictable procedural anchors because postoperative air, blood and fluid must be managed until clinically appropriate tube removal. Germany reported 28,843 isolated CABG procedures in 2024 and 45,422 isolated valve procedures, although 24,957 valve interventions were transcatheter and should not be treated as open-surgery chest-drain opportunities. [2] [7] Pneumothorax treatment represented 22.0%, or USD 0.238 billion, and is projected to grow at 6.7%. England’s 72,275 admissions from 2017 to March 2023 show the scale of inpatient-treated spontaneous pneumothorax, while NICE specifically includes pneumothorax among the situations in which Thopaz+ may be considered. [3] [6] Pleural effusion management held 27.0%, or USD 0.292 billion, with a 6.4% CAGR. A U.S. National Inpatient Sample analysis identified 126,825 malignant pleural-effusion hospitalizations in 2012; 72,240 included at least one pleural procedure and 23,035 included chest-tube placement. Although older, the dataset demonstrates the procedure intensity of hospitalized malignant pleural effusion. [8] Trauma care accounted for 13.0%, or USD 0.140 billion, and has the fastest application CAGR at 7.2%. British Thoracic Society guidance notes that larger-bore drains should be considered in unstable trauma patients and in pneumothorax complicating mechanical ventilation, preserving a distinct market for high-flow, blockage-resistant systems. [9] How Is Product Mix Shifting Toward Smaller-Bore and Digital Systems? Thoracic drainage tubes led with 46.0% of revenue, or USD 0.497 billion in 2025, and a 6.1% CAGR. BTS recommends small-bore chest tubes of 14F or less as initial drainage for pleural infection and states that small-bore drains are suitable for most indications, while larger drains retain a role in unstable trauma, substantial air leak and selected postoperative settings. Rocket Medical’s Seldinger portfolio illustrates this trend with 12F, 18F and 20F procedure-pack configurations. [9] [10] Collection chambers represented 34.0%, or USD 0.367 billion, and a 6.5% CAGR. Teleflex Pleur-Evac and Getinge Atrium remain important conventional franchises because hospitals continue to buy standardized water-seal, dry-suction and dry-seal configurations across postoperative, trauma and respiratory care. [16] [17] Suction devices accounted for 20.0%, or USD 0.216 billion, but have the fastest product CAGR at 7.0%. Digital systems differentiate through objective monitoring rather than suction alone. A contemporary review identified 14 randomized trials and four meta-analyses after pulmonary resection: six trials found shorter drainage duration or hospital stay, eight found no difference, and all four meta-analyses favored digital systems. Objective air-leak assessment was the more consistent advantage. [11] NICE estimates Thopaz+ can save about £108 per pulmonary-resection patient per hospital stay, mainly through shorter length of stay, and models about £8.5 million in annual savings in England. This matters because premium digital systems compete within a bundled hospital episode rather than through separate device reimbursement. [6] Which Care Settings and Procurement Models Matter Most? Hospitals represented 61.0% of the market, or USD 0.659 billion in 2025, with a 5.9% CAGR. Purchasing decisions extend beyond unit price to suction stability, tube compatibility, mobility, staff training, supply continuity and proprietary-disposable costs. Surgical centers accounted for 18.0%, or USD 0.194 billion, and a 6.8% CAGR. For SMR, this category includes specialty surgical hospitals and hospital-affiliated cardiothoracic centers. Clinics held 12.0%, or USD 0.130 billion, and a 6.7% CAGR, concentrated in selected pleural and respiratory interventions. Homecare providers represented 9.0%, or USD 0.097 billion, and have the fastest end-user CAGR at 8.4%. This is an ambulatory niche rather than a replacement for inpatient postoperative drainage. Redax markets WearABLE for outpatient care, while Sinapi positions LEVO XS100 for ambulatory/outpatient use. [13] [14] Procurement increasingly separates premium digital systems from conventional consumables. In February 2026, Medela’s Thopaz+ became the first system awarded in Vizient’s newly created digital chest-drainage category, while public tenders continue to sustain conventional chamber and tubing purchases. [15] How Do Reimbursement, Guidelines and Hospital Economics Shape Adoption? CMS’s 2026 NCCI manual recognizes tube thoracostomy under CPT 32551 and pleural drainage under codes including 32556 and 32557, but generally does not allow separate reporting of tube thoracostomy with another ipsilateral open thoracic procedure. This emphasizes episode economics rather than incremental device reimbursement. [12] NICE’s economic support for Thopaz+ is therefore relevant when reductions in drainage duration or length of stay offset equipment and consumable costs. NHS England’s MedTech Funding Mandate implementation support was due to graduate in August 2024, while NICE guidance remains active. [6] [19] BTS favors small-bore drains for pleural infection while retaining larger-bore systems for selected high-flow or unstable settings. Manufacturers therefore need portfolios spanning Seldinger kits, conventional chambers, portable drainage and digital suction. [9] Where Is the Chest Drainage System Market Growing Fastest? North America held 39.0% of the market, or USD 0.421 billion in 2025, and is projected to expand at 5.8%. The region combines large cardiac-surgery infrastructure with mature purchasing networks. Medela’s Vizient award improves access to U.S. hospital systems, while Centese competes with FDA-cleared Thoraguard. [1] [4] [15] Europe accounted for 27.0%, or USD 0.292 billion, and a 5.9% CAGR. NICE provides transparent digital-drain economics, while Germany’s CABG and surgical valve volumes support substantial open-surgery workload. [6] [7] Asia-Pacific represented 23.0%, or USD 0.248 billion, and has the fastest regional CAGR at 8.0%. Japan’s 94,961 thoracic procedures in 2024 demonstrate high procedural intensity, while Indian public procurement continues to support conventional underwater-seal bottles and thoracic consumables. [2] Latin America held 6.0%, or USD 0.065 billion, with a 6.6% CAGR. Hospital surgery, trauma and respiratory care remain the main commercial settings, with Teleflex supplying conventional dry-suction and water-seal systems. [16] Middle East & Africa accounted for 5.0%, or USD 0.054 billion, with a 6.7% CAGR. Tertiary-hospital and trauma-care investment supports the market, while South Africa-based Sinapi provides LEVO configurations for ambulatory, thoracic, cardiac and adult/pediatric use. [14] Which Companies Are Best Positioned in Chest Drainage Systems? Competition centers on product breadth, drainage reliability, objective monitoring, portability, catheter compatibility, recurring consumables, training and procurement access. Conventional franchises retain scale advantages, while digital suppliers compete for higher-value cardiothoracic accounts. Medela Medela is positioned around digital premiumization through Thopaz+, combining a reusable regulated-suction platform with disposable canisters and tubing. NICE support and the 2026 Vizient contract strengthen its commercialization case. [6] [15] Teleflex Teleflex competes through Pleur-Evac, including Sahara dry-suction/dry-seal systems and the Mini Sahara for patient mobility. Its strength is portfolio breadth and familiarity in conventional chest drainage. [16] Getinge Getinge’s Atrium family includes Oasis, Express and Ocean configurations. The portfolio is broad, but safety performance matters: FDA classified a correction involving Atrium Express and recalled sterile-water syringes as Class I, affecting 251,142 U.S. devices. [17] [18] Centese Centese differentiates Thoraguard through digital air-leak and fluid measurement and automated line clearing when used with its compatible chest-tube system. FDA granted 510(k) clearance in November 2018. [4] Redax Redax spans conventional and digital drainage through Drentech products, including SilverLine digital monitoring and portable ambulatory systems. This spans inpatient and selected outpatient pathways. [13] [22] Rocket Medical Rocket Medical is strongest in catheter and procedure-kit integration. Its Seldinger kits include guidewires, shorter dilators, fixation components and complete ward procedure packs in selected sizes. [10] Sinapi Biomedical Sinapi Biomedical positions LEVO around simple dry-seal drainage and mobility, with configurations for ambulatory/outpatient, thoracic, cardiac and adult/pediatric use. [14] What Recent Events Matter Most to Market Strategy? Three 2026 developments deserve particular attention. First, Medela’s February Vizient award created a dedicated U.S. contracting route for digital chest drainage. Second, NHS Supply Chain reported in July 2026 that Cardinal Health’s chest-drain discontinuation had affected 16 product codes, creating supplier-conversion opportunities. Third, NHS Supply Chain circulated a March 2026 Rocket Medical field safety notice concerning one affected lot in which an insertion needle could puncture the catheter wall; NHS Supply Chain reported that its stock had been checked and future supply would use unaffected inventory. [15] [20] [21] These events show how purchasing access, supply continuity and safety performance can shift share in both premium digital and mature disposable categories. How Will the Chest Drainage System Market Evolve Through 2032? The market is likely to retain a two-tier structure through 2032. Conventional tubes and collection chambers will remain the volume foundation because they fit broad hospital workflows, trauma care and price-sensitive tender procurement. Digital suction platforms will capture a larger share of premium cardiothoracic accounts where objective monitoring, mobility and standardized tube-removal pathways can support measurable operational savings. The fastest supplied growth rates are concentrated in homecare providers at 8.4%, Asia-Pacific at 8.0%, trauma care at 7.2% and suction devices at 7.0%. These segments point to four strategic themes: ambulatory care for selected patients, expansion of advanced thoracic services in Asia, continued need for reliable trauma systems, and digital premiumization of suction and monitoring. Competitive advantage will depend on reliable drainage, tube-size options, portability, objective monitoring, recurring consumables, training, procurement access and supply continuity. Hospital buyers will continue to test whether premium platforms improve workflow or episode economics enough to justify higher acquisition and consumable costs. Chest Drainage System Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.08 Billion Revenue Forecast in 2032 USD 1.67 Billion Overall Growth Rate CAGR of 6.4% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Application, By End User, By Geography By Product Type Thoracic Drainage Tubes, Collection Chambers, Suction Devices By Application Pneumothorax Treatment, Pleural Effusion Management, Post-Surgical Care, Trauma Care By End User Hospitals, Surgical Centers, Clinics, Homecare Providers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, Japan, India, China, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Large cardiothoracic and trauma procedure base, recurring demand for tubes and collection chambers, adoption of digital suction and monitoring, growth in ambulatory drainage, objective air-leak measurement, and expansion of thoracic services in Asia-Pacific Customization Option Available upon request Frequently Asked Question About This Report Q1. What are the latest innovations transforming the market? A1. Digital drainage platforms are replacing subjective bubble assessment with objective air-leak and fluid measurements. Battery-powered suction, automated monitoring, portable designs, and digital data tracking can support patient mobility and more standardized decisions about chest-tube removal. Q2. How is technology advancement influencing adoption in the industry? A2. Hospitals are increasingly evaluating systems that provide consistent regulated suction and real-time drainage information. Platforms such as Thopaz+ and Thoraguard can improve workflow by reducing dependence on visual interpretation while supporting standardized postoperative drainage protocols. Q3. What factors are encouraging adoption across different care settings in the market? A3. Smaller-bore catheters, portable systems, and ambulatory drainage products are extending use beyond traditional cardiothoracic wards. Specialty surgical centers, respiratory clinics, and selected homecare programs can now manage appropriate patients with less dependence on fixed wall suction. Q4. Which regions are expected to witness the fastest growth in the industry? A4. Asia-Pacific is expected to grow the fastest as thoracic surgery, trauma care, and advanced hospital infrastructure expand. Japan already has substantial thoracic procedure volumes, while broader healthcare investment across the region is increasing demand for both conventional and digital drainage systems. Q5. What strategies are companies adopting to strengthen their position in the market? A5. Companies are competing through broader catheter ranges, portable drainage, objective digital monitoring, recurring consumables, and hospital-contract access. Medela is strengthening digital positioning, while Teleflex and Getinge retain large conventional portfolios and companies such as Redax and Sinapi are expanding ambulatory options. Q6. What factors could limit future industry growth? A6. Premium digital systems must demonstrate enough improvement in drainage duration, hospital stay, or workflow to justify higher equipment and consumable costs. Product recalls, supply interruptions, staff-training requirements, and continued availability of inexpensive conventional systems can also slow conversion. Source List: [1] Society of Thoracic Surgeons – STS National Database [2] PMC – General Thoracic and Cardiovascular Surgery Procedure Data [3] PMC – Spontaneous Pneumothorax Admissions in England [4] FDA – Thoraguard 510(k) Clearance K181667 [6] NICE – Thopaz+ Recommendations [7] PubMed – German Cardiac Surgery Procedure Statistics [8] PubMed – Malignant Pleural Effusion Hospitalizations and Procedures [9] British Thoracic Society – Pleural Disease Guideline [10] Rocket Medical – Seldinger Chest Drainage Kits [11] PMC – Digital Chest Drainage After Pulmonary Resection Review [12] CMS – 2026 NCCI Medicare Policy Manual, Chapter 5 [13] Redax – WearABLE Portable Chest Drain [14] Sinapi Biomedical – LEVO Drainage Systems [15] Medela – Vizient Digital Chest Drainage Contract [16] Teleflex – Pleur-Evac Dry-Suction and Dry-Seal Systems [17] Getinge – Atrium Chest Drain Education [18] FDA – Atrium Express Class I Recall [19] NHS England – MedTech Funding Mandate Policy Guidance [20] NHS Supply Chain – Cardinal Health Chest-Drain Product Update [21] NHS Supply Chain – Rocket Medical Field Safety Notice [22] Redax – Drentech SilverLine Table of Contents - Global Chest Drainage System Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Application, and End User Investment Opportunities in the Chest Drainage System Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Thoracic Drainage Tubes, Collection Chambers, Suction Devices, Digital Drainage Platforms, Portable Drainage, and Ambulatory Thoracic Care Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Chest Drainage Systems in Post-Surgical Care, Pneumothorax Treatment, Pleural Effusion Management, and Trauma Care Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Reimbursement, Clinical Guidelines, Safety, and Hospital Procurement Factors Role of Digital Suction, Objective Air-Leak Monitoring, Portable Drainage, and Ambulatory Care in Market Expansion Shift Toward Smaller-Bore Tubes, Digital Monitoring, Mobility, and Standardized Chest-Tube Management Global Chest Drainage System Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Thoracic Drainage Tubes Collection Chambers Suction Devices Market Analysis by Application: Pneumothorax Treatment Pleural Effusion Management Post-Surgical Care Trauma Care Market Analysis by End User: Hospitals Surgical Centers Clinics Homecare Providers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Chest Drainage System Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: United States Canada Mexico Europe Chest Drainage System Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Chest Drainage System Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Chest Drainage System Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Chest Drainage System Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, and End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Medela Teleflex Incorporated Getinge AB Centese, Inc. Redax S.p.A. Rocket Medical plc Sinapi Biomedical ConvaTec Group Plc Cook Medical Becton, Dickinson and Company Cardinal Health, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Drainage Reliability, Digital Monitoring Capability, Portability, Tube Compatibility, Recurring Consumables, Training, Procurement Access, and Regional Presence Supplier Qualification and Clinical Compliance Capability Analysis Digital Chest Drainage and Objective Monitoring Positioning Thoracic Drainage Tube and Collection Chamber Competitiveness Portable, Ambulatory, and Homecare Drainage Strategy Analysis Hospital Procurement, Supply Continuity, and Product Safety Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Application, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Clinical Guidelines, Procurement, Reimbursement, and Safety Risk Analysis Technology Adoption Trends Across Thoracic Drainage Tubes, Collection Chambers, Suction Devices, Digital Drainage, Portable Drainage, and Ambulatory Care List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Application, and End User (2025 vs. 2032) Global Chest Drainage System Ecosystem and Value Chain Analysis